[
  {
    "ts": null,
    "headline": "Contract research firms' strong earnings signal stabilizing biotech, pharma spending",
    "summary": "(Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a cautious stretch driven by tighter sector financing.  Danaher, Medpace, IQVIA, ICON and Thermo Fisher have posted strong results owing to steady demand from the industry for tools and services that are used in the development of novel medicines.  \"Biotech funding has started to tick up month over month from April to June, and perhaps our biggest takeaway from IQVIA results as well as Medpace is that the macro environment, while still challenged, has perhaps stabilized,\" said TD Cowen analyst Charles Rhyee.",
    "url": "https://finnhub.io/api/news?id=388cae48c142f57143332a98c9038540278e95eb8111e4331a4da39ee2adbff5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753378735,
      "headline": "Contract research firms' strong earnings signal stabilizing biotech, pharma spending",
      "id": 136085051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "(Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a cautious stretch driven by tighter sector financing.  Danaher, Medpace, IQVIA, ICON and Thermo Fisher have posted strong results owing to steady demand from the industry for tools and services that are used in the development of novel medicines.  \"Biotech funding has started to tick up month over month from April to June, and perhaps our biggest takeaway from IQVIA results as well as Medpace is that the macro environment, while still challenged, has perhaps stabilized,\" said TD Cowen analyst Charles Rhyee.",
      "url": "https://finnhub.io/api/news?id=388cae48c142f57143332a98c9038540278e95eb8111e4331a4da39ee2adbff5"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Corp. stock outperforms competitors on strong trading day",
    "summary": "Danaher Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=4a80baf89cec719c3a41dd4c411891c25a0059e7b4aabb740b565a4e5ffa1489",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753374960,
      "headline": "Danaher Corp. stock outperforms competitors on strong trading day",
      "id": 136123440,
      "image": "",
      "related": "DHR",
      "source": "MarketWatch",
      "summary": "Danaher Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=4a80baf89cec719c3a41dd4c411891c25a0059e7b4aabb740b565a4e5ffa1489"
    }
  },
  {
    "ts": null,
    "headline": "CVS or DHR: Which Is the Better Value Stock Right Now?",
    "summary": "CVS vs. DHR: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=c3c8fc4d56ac4733e32f0848bd50e15d4643e3b9a1ff1c249f4bcfe80d28c3a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753371603,
      "headline": "CVS or DHR: Which Is the Better Value Stock Right Now?",
      "id": 136085146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "CVS vs. DHR: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=c3c8fc4d56ac4733e32f0848bd50e15d4643e3b9a1ff1c249f4bcfe80d28c3a1"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Q2 2025 Update",
    "summary": "While S&P 500 is at its all-time high, Danaher is still ~34% below its peak from late 2021. Click to read.",
    "url": "https://finnhub.io/api/news?id=a07db77355517037fc33a2e28e451af352ff14635ac0efbab847866ea528b19d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753371000,
      "headline": "Danaher Q2 2025 Update",
      "id": 136072376,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311598658/image_1311598658.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "While S&P 500 is at its all-time high, Danaher is still ~34% below its peak from late 2021. Click to read.",
      "url": "https://finnhub.io/api/news?id=a07db77355517037fc33a2e28e451af352ff14635ac0efbab847866ea528b19d"
    }
  },
  {
    "ts": null,
    "headline": "Akre Focus Fund Q2 2025 Commentary",
    "summary": "Akre Focus Fund Q2 update highlights quality-driven compounding over bounce-driven gains. Learn why patience and selectivity pay off long term.",
    "url": "https://finnhub.io/api/news?id=4eb3b32b2c6f43f0d807170aaf4beabda22d805a71bdda2f0f69185f93b34e07",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753326000,
      "headline": "Akre Focus Fund Q2 2025 Commentary",
      "id": 136063834,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357752804/image_1357752804.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "Akre Focus Fund Q2 update highlights quality-driven compounding over bounce-driven gains. Learn why patience and selectivity pay off long term.",
      "url": "https://finnhub.io/api/news?id=4eb3b32b2c6f43f0d807170aaf4beabda22d805a71bdda2f0f69185f93b34e07"
    }
  }
]